BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
Data from Summit Therapeutics Inc . (NASDAQ: SMMT ) and their partner Akeso for ivonescimab (PD-1xVEGF bispecific) has shown the potential to challenge standard-of-care regimens across a range of solid tumors The analyst notes that the data for ivonescimab have sparked interest in BioNTech's bispecific drug, BNT327, and its potential to follow a similar path and gain value. Also Read: BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3 The analyst adds that the data for BNT327, including the latest findings presented at the European Society for Medical Oncology, show a promising clinical profile. While direct comparisons with other trials have limitations, this data supports growing confidence in reducing risks and points to significant potential opportunities for BioNTech in various cancer treatments. Goldman Sachs has upgraded BioNTech to Buy from Neutral, with a price target of $137, up from the previous target of $90 “We see the investment thesis in BNTX continui
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Where Will Summit Therapeutics Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
- 3 Stocks That Could Turn $1,000 into $5,000 by 2030 [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.MarketBeat
SMMT
Earnings
- 10/30/24 - Beat
SMMT
Sec Filings
- 1/6/25 - Form 4
- 1/6/25 - Form 4
- 1/6/25 - Form 4
- SMMT's page on the SEC website